Positive clinical trial results are critical milestones for biotech companies, often leading to increased investor confidence and stock price gains. The achievement of all primary and secondary endpoints in the Phase 2 trial suggests that EYP-1901 has a high potential for progressing to the next stages of development and eventually commercialization, which is a significant driver for the company's valuation in the short term.